Tokyo Tape
Sign in
← Kirin Holdings

Quarterly report · Q1

2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥501.8bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥450.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥30.8bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥11.0bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥44.2bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥20.1bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥25.9bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥5.6bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥32.6bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥11.3bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.00Tat 2024-03-31Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.47Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.55Tat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.46Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.23Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.16Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥971.9bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥151.2bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥116.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥39.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥41.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥65.3bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.4bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥34.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥8.6bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥31.982024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥6.92023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥31.982024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥6.92023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio38.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.4%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥20.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥4.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥15.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31−¥158m
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥12.3bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥238.6bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥238.2bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥379m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2024-01-01 → 2024-03-31¥32.7bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2024-01-01 → 2024-03-31¥31.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥726m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2024-01-01 → 2024-03-31−¥1.7bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥122.2bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥121.5bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥645m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥12.2bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥105.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥105.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥67m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥22.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥16.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31−¥265m
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥11.5bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥225.4bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥225.1bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥300m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥20.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2023-01-01 → 2023-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2023-01-01 → 2023-03-31¥17.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥991m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2023-01-01 → 2023-03-31−¥1.4bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥108.6bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥108.0bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥609m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥9.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥93.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥93.4bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥107m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥16.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 779
ItemContextValueUnit
Liabilities and equity IFRSCurrentQuarterInstant3004699000000JPY
Revenue IFRSPrior1YTDDuration450329000000JPY
Revenue IFRSCurrentYTDDuration501762000000JPY
Cost of sales IFRSPrior1YTDDuration245883000000JPY
Cost of sales IFRSCurrentYTDDuration273013000000JPY
Gross profit IFRSPrior1YTDDuration204446000000JPY
Gross profit IFRSCurrentYTDDuration228749000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration170873000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration195694000000JPY
Other operating income IFRSPrior1YTDDuration3222000000JPY
Other operating income IFRSCurrentYTDDuration3231000000JPY
Other operating expenses IFRSPrior1YTDDuration25803000000JPY
Other operating expenses IFRSCurrentYTDDuration5457000000JPY
Operating profit loss IFRSPrior1YTDDuration10992000000JPY
Operating profit loss IFRSCurrentYTDDuration30829000000JPY
Finance income IFRSPrior1YTDDuration1949000000JPY
Finance income IFRSCurrentYTDDuration6667000000JPY
Finance costs IFRSPrior1YTDDuration1363000000JPY
Finance costs IFRSCurrentYTDDuration2341000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration8485000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration9017000000JPY
Profit loss before tax IFRSPrior1YTDDuration20063000000JPY
Profit loss before tax IFRSCurrentYTDDuration44172000000JPY
Income tax expense IFRSPrior1YTDDuration8737000000JPY
Income tax expense IFRSCurrentYTDDuration11586000000JPY
Profit loss IFRSPrior1YTDDuration11326000000JPY
Profit loss IFRSCurrentYTDDuration32586000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration5591000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration25900000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration5736000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration6686000000JPY
Profit loss IFRSPrior1YTDDuration11326000000JPY
Profit loss IFRSCurrentYTDDuration32586000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration6.90
Basic earnings loss per share IFRSCurrentYTDDuration31.98
Diluted earnings loss per share IFRSPrior1YTDDuration6.90
Diluted earnings loss per share IFRSCurrentYTDDuration31.98
Profit loss IFRSPrior1YTDDuration11326000000JPY
Profit loss IFRSCurrentYTDDuration32586000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration2926000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration1235000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration－JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration127000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-1476000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-684000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration26916000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration44385000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration857000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration2715000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration-6067000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass